Abstract: A technique is provided for determining a force/acceleration acting on a proof mass of a bistable device. According to an aspect of the invention, the location of a boundary of one of the stable configurations of the device is monitored. The monitored location is compared to a predetermined location of the same boundary, said predetermined location corresponding to a condition in which the force/acceleration is absent, to detect a deviation of said location. The deviation is indicative of the force/acceleration and can be used to determine the force/acceleration. According to another aspect of the invention, the resonance frequency of the proof mass' oscillation in one of the stable regions is monitored, and compared to a predetermined resonance frequency the proof mass' oscillation in the same region corresponding to a condition in which the force/acceleration is absent, to determine a deviation of the resonance frequency due to the presence of force/acceleration.

Abstract: The present invention provides a humanized anti-HMGB1 antibody which specifically binds to a sequence consisting of the C-terminal 8 amino acid residues (EEEDDDDE) of HMGB1 protein and is effective for treatment or prevention of various inflammatory diseases related to this protein, as well as an antigen-binding fragment thereof. The present invention also provides a pharmaceutical composition comprising such an antibody or antigen-binding fragment thereof.

Abstract: Reactive and modified M13 bacteriophages, and methods of making and using the same, are generally provided. The reactive M13 bacteriophage can include a alkyne functional group covalently attached to the M13 bacteriophage. The modified M13 bacteriophage can include a substituent covalently attached to the M13 bacteriophage via a 1,2,3-triazole linkage. Dual-modified M13 bacteriophages are also generally provided, and can include a cancer-targeting substituent covalently attached to the M13 bacteriophage and a fluorescent group covalently attached to the M13 bacteriophage. The modified M13 bacteriophages can not only be employed as a fluorescent probe for cancer imaging, but also can be used as biomaterials for cell alignment and scaffolding.

Abstract: The invention provides for a method for aggregating dermal papilla cells or dermal sheath cells or a combination thereof, the method comprising: growing dermal papilla cells or dermal sheath cells or a combination thereof in suspension culture; and contacting the culture with an effective amount of an enzyme, wherein a substrate of the enzyme is an extracellular matrix molecule in the suspension culture, so as to aggregate dermal papilla cells or dermal sheath cells. The culture may be a hanging drop culture and the enzyme may be a hyaluronidase.

Abstract: Provided are ATP-binding cassette transporters (ABC transporters). More specifically, the present disclosure relates to ABC terpenoid transporters, nucleic acid sequences, amino acids, proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.

Abstract: An inputting fingertip sleeve includes a sleeve and an inputting end. The sleeve includes at least one opening configured to receive a finger. The inputting end is fixed on the sleeve. The inputting end is a carbon nanotube structure. The carbon nanotube structure is a substantially pure structure of carbon nanotubes and comprises a plurality of carbon nanotubes.

Abstract: Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved by increasing the miR-142 and/or miR-223 polynucleotides in a MDSC.

Abstract: Disclosed herein are an apparatus and a process that can be used to remove sulfur dioxide other environmentally hazardous contaminants from a gaseous waste stream while at the same time providing a source of purified water. The process can be used for the desalination of sea or brackish water, or for the concentration of contaminated waste water. The method comprises feeding a gaseous waste stream that comprises sulfur dioxide into a diffusion tower. Feed water is sprayed onto a packing material in the diffusion tower to form a thin film of feed water on a surface of the packing material. Sulfur dioxide diffuses into the thin film of feed water to form water that contains sulfur dioxide. The gaseous waste stream is simultaneously humidified. The humidified gaseous waste stream is then subjected to direct contact condensation to obtain purified water.

Abstract: Fuel cell systems comprising ammonia borane or derivatives thereof as fuel and an anode and/or cathode which comprises a non-noble metal (e.g., copper) or a non-metallic substance (e.g., an iron electron-transfer mediating complex) as a catalyst are disclosed. Fuel cell systems comprising ammonia borane or derivatives thereof as fuel and a peroxide as an oxidant are also disclosed. Uses of the fuel devices are further disclosed.

Abstract: Antibodies for detecting nitration of nitrotyrosine 247 PKG-1? and antibodies for detecting nitrotyrosine 425 of PKG-1? are disclosed. Methods of detecting nitrotyrosine 247 PKG-1? and nitrotyrosine 425 of PKG-1?, and uses thereof are also disclosed for identification and diagnosis or phenotypes, pathologies, diseases and disorders associated with protein nitration of PKG-1? are also disclosed. In a preferred embodiment, one or more of the disclosed antibodies is used in the disclosed methods.

Abstract: There is provided a System and Method For Determining The Radiological Composition of Material Layers Within a Conduit. The system and method disclosed is equally applicable to pipes, vessels, and conduits as well as medical applications such as determining vessel thickness, occlusion, scarring, or the like in humans and animals. A phantom setup is disclosed that has a phantom containing a test standard such as a reactor water test standard, removable plates, a collimator and probe with a spectrometer display. The phantom setup provides a baseline data set that can be used in conjunction with field measurements to determine the composition of materials within the conduit, such as corrosion or the like. The baseline data set may be semi-logarithmic and contains spectrometer readings of various plate thicknesses or quantities of plates.

Abstract: A composition for inducing differentiation into beige adipocytes from white adipocytes, including butein, a butein derivative, or a pharmaceutically available salt thereof as an active ingredient, and a method of inducing the differentiation are provided. Increases in expressions of UCP-1 and PRDM4 are confirmed using the active ingredient, that is, the butein or butein derivative, and therefore the composition is expected to be used in preventing or treating obesity, and more basically, for target treatment.

Abstract: The disclosure relates to an earphone. The earphone includes a housing, a first speaker located in the housing and configured to play a first sound in a high frequency range, and a second speaker located in the housing and configured to play a second sound in a low frequency range or a middle frequency range. The first speaker includes a thermoacoustic device unit including a sound wave generator including carbon nanotube structure. The second speaker is an electric loudspeaker, electromagnetic speaker, or capacitive speaker.

Abstract: Provided to a transgenic tree induced by RabG3bCA and a use thereof. The transgenic tree serves to control xylem growth through RabG3b of Arabidopsis thaliana, and this function is involved in the growth of poplars. Particularly, the transgenic tree is valuable for industrial use since the increase in length of a fiber cell, which is the most important factor of determining pulp quality, is confirmed.

Abstract: A chip resistor having terminal electrodes is provided. In the chip resistor, a first protector layer has a size different from that of a first resistor layer. Thus, two ends of the first resistor layer are exposed to form new current conduction path. Original current conduction path having the same size of the protective layer and the resistor layer is thus replaced. Hence, resistance variation of the chip resistor is solved; yield of the chip resistor is increased; and, the material cost of the front terminal electrode is greatly reduced.

Abstract: An iridium complex represented by formula (1) and an OLED using the same are shown. In Formula (1), l, m, n, p, b, R1-R6, X1-X6, A1, A2 and B are the same as defined in the specification. The iridium complex is able to emit a range of visible light with high color purity and high efficiency as neat sample.

Abstract: In various embodiments, a device for testing a battery may be provided. The device for testing a battery may include: a determination circuit configured to determine at least one of a differential enthalpy of the battery and a differential entropy of the battery; and an evaluation circuit configured to evaluate a health state of the battery based on the determined at least one of the differential enthalpy and the differential entropy.

Abstract: A method is disclosed for measuring the properties of protein and lipoprotein elements in a sample.

Abstract: Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring.

Abstract: A method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Dravet Syndrome patients are typically children under the age of 18 and are treated at a preferred dose of less than about 0.5 to about 0.01 mg/kg/day.